-5%
Vildagliptin is a DPP-4 (Dipeptidyl Peptidase-4) inhibitor that helps regulate blood sugar by preventing the breakdown of incretin hormones. Incretins such as GLP-1 and GIP are produced in the intestine and increase after eating. These hormones stimulate insulin release from pancreatic β-cells and reduce glucagon secretion from α-cells when blood glucose levels are normal or high. They are normally degraded quickly by DPP-4.
By blocking DPP-4, Vildagliptin increases the levels and prolongs the action of these incretin hormones, which enhance insulin secretion and lower glucagon in a glucose-dependent manner, helping maintain better glycemic control.
Vildapin is prescribed as an add-on therapy to diet and exercise to help improve blood glucose control in adults with type 2 diabetes mellitus. It may be used:
As monotherapy when diet and exercise alone do not provide sufficient glycemic control.
In combination therapy with Metformin, a Sulfonylurea, a Thiazolidinedione, or Insulin when diet, exercise, and a single oral antidiabetic agent fail to adequately control blood glucose.
Vildagliptin is not recommended during pregnancy.
It should also be avoided during breastfeeding due to insufficient safety data.